Nalu Medical is a Carlsbad, California–based medtech company focused on innovative, minimally invasive, non‑pharmacologic solutions for chronic neuropathic pain. Its Nalu Neurostimulation System uses a battery‑free, miniaturized implantable pulse generator (micro‑IPG) powered wirelessly by an externally worn Therapy Disc and controlled via a smartphone app. The micro‑IPG delivers capabilities similar to larger IPGs while offering advanced waveforms, extensive programming options, upgradability, and an expected service life of 18 years. The system is FDA‑cleared for both spinal cord stimulation (SCS) and peripheral nerve stimulation (PNS). The company plans to use recent proceeds to accelerate commercial growth, expand clinical and health‑economic evidence, continue product development, scale operations, and build clinical data to support expanded access and payor coverage. B Capital noted the company is at a time of high revenue growth, and Nalu recently completed an $85M Series E equity raise. Nalu Medical develops a proprietary neurostimulation system that delivers electrical pulses via a fully featured, battery-free, miniaturized implantable pulse generator (IPG) to modulate pain signals before they reach the brain. The system is FDA-cleared for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications and is controlled through a smartphone-based remote app with an externally worn Therapy Disc for wireless power. Nalu emphasizes a small-form-factor IPG that offers advanced waveforms, extensive programming, upgradability, and an expected service life of 18 years. The company positions its technology as an alternative for patients who have failed conventional treatments, providing pain relief without the need for opioids. Nalu is expanding commercialization and pursuing clinical research to drive growth and broaden patient access. The company has received industry recognition, including placement among the world’s top 100 new products by R&D Magazine in 2021. Nalu Medical develops and commercializes minimally invasive neurostimulation systems to treat chronic neuropathic pain. Its Nalu Neurostimulation System includes a fully featured, battery-free, miniaturized implantable pulse generator (IPG) that is powered wirelessly by an externally worn Therapy Disc and controlled via a smartphone-based remote control app. The system is FDA-cleared for both Spinal Cord Stimulation (SCS) and Peripheral Nerve Stimulation (PNS) indications, with trial devices intended for ≤30-day stimulation trials prior to permanent implantation. Led by President and CEO Earl Fender, the company focuses on expanding clinical evidence and continuing product development. Nalu intends to use new financing to scale commercial operations, accelerate growth, expand clinical evidence, and support ongoing product development and general corporate purposes.

Total raised

$169M

Funding rounds

3

Latest round

Series E

Latest activity

Mar 2024